Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group.
Emergency department
Mortality
Triage
suPAR
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
05
03
2020
pubmed:
14
5
2020
medline:
14
5
2020
entrez:
14
5
2020
Statut:
ppublish
Résumé
In light of the accumulating evidence on the negative predictive value of soluble urokinase plasminogen activator receptor (suPAR), a group of experts from the fields of intensive care medicine, emergency medicine, internal medicine and infectious diseases frame a position statement on the role of suPAR in the screening of patients admitted to the emergency department. The statement is framed taking into consideration existing publications and our own research experience. The main content of this statement is that sUPAR is a non-specific marker associated with a high negative predictive value for unfavourable outcomes; levels < 4 ng/ml indicate that it is safe to discharge the patient, whereas levels > 6 ng/ml are an alarming sign of risk for unfavourable outcomes. However, the suPAR levels should always be interpreted in light of the patient's history.
Identifiants
pubmed: 32399855
doi: 10.1007/s40121-020-00301-w
pii: 10.1007/s40121-020-00301-w
pmc: PMC7217599
doi:
Types de publication
Letter
Langues
eng
Pagination
407-416Références
Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: the unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents. 2015;46S:S33–S34.
doi: 10.1016/j.ijantimicag.2015.10.011
Dinesh P, Rassol M. uPAR/suPAR signaling in rheumatoid arthritis: shedding light on its mechanism of action. Pharmacol Res. 2018;134:31–9.
doi: 10.1016/j.phrs.2018.05.016
Liu KL, Fan JH, Wu J. Prognostic role of circulating soluble uPAR in various cancers: a systematic review and meta-analysis. Clin Lab. 2017;63:871–80.
pubmed: 28627814
de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13–39.
doi: 10.1002/med.10054
Chounta A, Ellinas C, Tzanetakou V, et al. Serum soluble urokinase plasminogen actvator receptor as a screening tool for the early diagnosis of hepatocellular carcinoma. Liver Int. 2015;35:601–7.
doi: 10.1111/liv.12705
Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916–25.
doi: 10.1056/NEJMoa1506362
Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney disease. N Engl J Med. 2020;382:416–26.
doi: 10.1056/NEJMoa1911481
Hayek SS, Koh KH, Graims ME, et al. A tripartite complex of suPAR, APOL1 risk variants and α
doi: 10.1038/nm.4362
Winnick W, Sunder-Plassmann G, Sengölge G, et al. Diagnostic and prognostic value of soluble urokinase-type plasminogen activator receptor (suPAR) in focal segmental glomelurosclerosis and impact of detection method. Sci Rep. 2019;9:13783.
doi: 10.1038/s41598-019-50405-8
Schultz M, Raamussen LJH, Kallemose T, et al. Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. Scand J Traum Res Emerg Med. 2019;27:43.
doi: 10.1186/s13049-019-0621-7
Schultz M, Rasmussen LJH, Høi-Hansen T, et al. Early discharge from the emergency department based on soluble urokinase plasminogen activator receptor (suPAR) levels: a TRIAGE III substudy. Dis Markers. 2019;2019:3403549.
doi: 10.1155/2019/3403549
Velissaris D, Pierrakos C, Karamouzos V, Pantzaris ND, Gogos C. The use of soluble urokinase plasminogen activator receptor (suPAR) as a marker of sepsis in the emergency department setting. A current review. Acta Clin Belg. 2019;21:1–6.
doi: 10.1080/17843286.2019.1653519
Rovina N, Akinosoglou K, Eugen-Olsen J, Salim H, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020; 24: 187
doi: 10.1186/s13054-020-02897-4
pubmed: 32354367
pmcid: 7191969
Savva A, Raftogiannis M, Baziaka F, et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect. 2011;63:344–50.
doi: 10.1016/j.jinf.2011.07.016
Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, et al. Risk assessment in sepsis: a new prognostication score by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16:R149.
doi: 10.1186/cc11463
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.
doi: 10.1097/01.CCM.0000217961.75225.E9
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
doi: 10.1001/jama.2016.0287
Giamarellos-Bourboulis EJ, Tsaganos T, Tsangaris I, et al. Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. Clin Microbiol Infect. 2017;23:104–9.
doi: 10.1016/j.cmi.2016.11.003
A suPAR-guided double-blind randomized clinical trial of initiation of antibiotics for presumed infection at the emergency department. https://clinicaltrials.gov/ct2/show/NCT03717350 .